HIGHLIGHTS
- who: Huiqin Liu from the Department of Medical Insurance, Cancer Prevention and Treatment University of Traditional Chinese Medicine), Chengdu, China have published the Article: Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non-small cell lung cancer in China, in the Journal: (JOURNAL)
- what: The aim of this study was to evaluate the cost efectiveness of sintilimab plus chemotherapy versus Platinum-based chemotherapy for locally advanced or metastatic squamous NSCLC in China. Treatment costs This analysis adopted a health care perspective in China . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.